Radiomedix

About Radiomedix

RadioMedix, Inc. operates as a clinical-stage biotechnology company from Houston, Texas, specializing in the development of targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of cancer. The company was founded in 2006 by Dr. Ebrahim S. Delpassand, Dr. Izabela Tworowska, and Azar Delpassand. Dr. Delpassand, the current Chairman and CEO, is a board-certified nuclear medicine physician with extensive experience in oncology, including a tenure as Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center. His journey from academia to private practice was driven by a desire to accelerate clinical research, leading to the establishment of Excel Diagnostics and Nuclear Oncology Center, which provided the necessary infrastructure for research, and subsequently, RadioMedix. Co-founder and Chief Scientific Officer, Dr. Tworowska, is a seasoned expert in clinical pharmacy and chemistry, focusing on the design of theranostic agents targeting cancer cells. Her background in organic and bioconjugate chemistry is central to the company's research and development efforts.

The company's business model encompasses the entire lifecycle of radiopharmaceutical development, from drug discovery and preclinical evaluation to cGMP manufacturing and commercialization. RadioMedix generates revenue through its service facilities, which provide contract development and manufacturing (CDMO) services to academic and industrial partners, and through the commercialization of its proprietary drug pipeline. The company serves the oncology market, providing tools for medical scientists and therapies for patients with aggressive and rare cancers. As of October 2022, RadioMedix had raised a total of $40 million in funding, including a significant Series A round to advance its pipeline.

RadioMedix is developing a portfolio of diagnostic and therapeutic agents based on alpha and beta-emitting isotopes like Ac-225, Lu-177, and Pb-212. A key product in their late-stage pipeline is AlphaMedix™ (212Pb-DOTAMTATE), a Targeted Alpha Therapy (TAT). This therapy uses a somatostatin receptor (SSTR)-targeting molecule combined with lead-212, an isotope that emits high-energy alpha particles. These particles can kill cancer cells with high specificity, minimizing damage to surrounding healthy tissue. In February 2024, the FDA granted Breakthrough Therapy Designation to AlphaMedix™ for treating a specific type of neuroendocrine tumor (GEP-NETs), highlighting its potential to offer substantial benefits over existing treatments. The FDA had previously granted it Orphan Drug Designation in 2018. The company also commercializes generator-produced radiopharmaceuticals based on Gallium-68 chemistry and received FDA approval for 64Cu-Dotatate (Detectnet™) in 2020 for imaging neuroendocrine tumors.